Literature DB >> 24887384

BEAM-conditioned autologous SCT improves the quality of response in Waldenström's macroglobulinaemia and lymphoplasmacytic lymphoma: a single centre's 10-year experience.

M A V Marzolini1, K J Thomson1, J Dorman1, S D'Sa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24887384     DOI： 10.1038/bmt.2014.113

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  9 in total

Review 1.  Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Meletios Athanasios Dimopoulos; Morie A Gertz; Efstathios Kastritis; Ramon Garcia-Sanz; Eva K Kimby; Veronique Leblond; Jean-Paul Fermand; Giampaolo Merlini; Pierre Morel; Enrica Morra; Enrique M Ocio; Roger Owen; Irene M Ghobrial; John Seymour; Robert A Kyle; Steven P Treon
Journal:  J Clin Oncol       Date:  2008-12-01       Impact factor: 44.544

2.  High-dose therapy with autologous PBSC transplantation in the front-line treatment of Waldenstrom's macroglobulinemia.

Authors:  T Caravita; A Siniscalchi; A Tendas; L Cupelli; T Dentamaro; G Natale; A Spagnoli; P de Fabritiis
Journal:  Bone Marrow Transplant       Date:  2008-11-03       Impact factor: 5.483

3.  Autologous stem cell transplantation as a care option in Waldenström's macroglobulinemia.

Authors:  Saad Usmani; Rachel Sexton; John Crowley; Bart Barlogie
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-02

4.  High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Charalampia Kyriakou; Carmen Canals; David Sibon; Jean Yves Cahn; Majid Kazmi; William Arcese; Karin Kolbe; Norbert Claude Gorin; Kristy Thomson; Noel Milpied; Dietger Niederwieser; Karel Indrák; Paolo Corradini; Anna Sureda; Norbert Schmitz
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

5.  Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.

Authors:  Constantine Tam; John F Seymour; Michael Brown; Philip Campbell; John Scarlett; Craig Underhill; David Ritchie; Rodney Bond; Andrew P Grigg
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

6.  Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.

Authors:  J Tamburini; V Lévy; C Chaleteix; J P Fermand; A Delmer; L Stalniewicz; P Morel; F Dreyfus; M J Grange; B Christian; S Choquet; V Leblond
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

7.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Authors:  Roger G Owen; Robert A Kyle; Marvin J Stone; Andy C Rawstron; Veronique Leblond; Giampaolo Merlini; Ramon Garcia-Sanz; Enrique M Ocio; Enrica Morra; Pierre Morel; Kenneth C Anderson; Christopher J Patterson; Nikhil C Munshi; Alessandra Tedeschi; Douglas E Joshua; Efstathios Kastritis; Evangelos Terpos; Irene M Ghobrial; Xavier Leleu; Morie A Gertz; Stephen M Ansell; William G Morice; Eva Kimby; Steven P Treon
Journal:  Br J Haematol       Date:  2012-11-15       Impact factor: 6.998

8.  Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide.

Authors:  Meletios A Dimopoulos; George Hamilos; Eleni Efstathiou; Ioannis Siapkaras; Charis Matsouka; Dimtra Gika; Vassiliki Grigoraki; Christos Papadimitriou; Dimitrios Mitsibounas; Nikolaos Anagnostopoulos
Journal:  Leuk Lymphoma       Date:  2003-06

Review 9.  How I treat Waldenström macroglobulinemia.

Authors:  Steven P Treon
Journal:  Blood       Date:  2009-07-17       Impact factor: 22.113
  9 in total
  1 in total

Review 1.  Waldenström macroglobulinemia treatment algorithm 2018.

Authors:  Morie A Gertz
Journal:  Blood Cancer J       Date:  2018-05-01       Impact factor: 11.037
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.